Get the Stockscreener App
8.00
0.38%
0.03
After Hours:
8.03
0.03
+0.37%
Immunitybio Inc stock is traded at $8.00, with a volume of 13.02M.
It is up +0.38% in the last 24 hours and up +3.90% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.97
Open:
$8.3442
24h Volume:
13.02M
Relative Volume:
0.54
Market Cap:
$8.38B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-20.52
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-1.36%
1M Performance:
+3.90%
6M Performance:
+280.95%
1Y Performance:
+181.69%
1-Day Range:
$7.74
$8.53
1-Week Range:
$7.74
$8.53
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.00 | 8.35B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S. - TipRanks
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th - GlobeNewswire Inc.
ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory - TradingView
Exclusive Tokyo BCG supply deal expands ImmunityBio (NASDAQ: IBRX) options - Stock Titan
ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess - GuruFocus
$IBRX DEADLINE: Immunitybio Inc. Investors Who Lost Money Should Contact Block & Leviton Before May 26th Deadline - marketscreener.com
ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - Carroll County Mirror-Democrat
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - marketscreener.com
IMMUNITYBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors ... - Caledonian Record
Kessler Topaz Meltzer & Check, LLP Announces the Filing of - GlobeNewswire
IBRX 8-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - PR Newswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the ... - Caledonian Record
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ImmunityBio Shares Rise After Securing Five New U.S. Patents for Bladder Cancer Therapy (IBRX) - Yahoo Finance
What's Going On With ImmunityBio Stock Monday?ImmunityBio (NASDAQ:IBRX) - Benzinga
Why Is IBRX Stock Rising Today? - Stocktwits
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open - TechStock²
ImmunityBio stock gains on five new U.S. patent awards - Investing.com India
ImmunityBio announces comprehensive U.S. patents covering combination of Anktiva with BCG for cancer treatment - marketscreener.com
ImmunityBio receives five U.S. patents for cancer treatment - Investing.com
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 - Business Wire
ImmunityBio Secures Exclusive Rights to Develop, Commercialize Tokyo-172 BCG in US - marketscreener.com
ImmunityBio Signs exclusive US agreement with Japan BCG Laboratory - BioSpectrum Asia
Countdown begins for IBRX founder Patrick Soon-Shiong’s much anticipated AUA talk – a look at what he intends to address on Saturday - MSN
IBRX Stock Rises Overnight: Investors Eye FDA Workshop On Anktiva After Exclusive Japan BCG Deal - Stocktwits
ImmunityBio announces partnership to expand access to Anktiva across 30 countries - MSN
ImmunityBio (IBRX) Secures U.S. Development Rights for Tokyo BCG Strain - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is ‘almost there’ - MSN
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus - TechStock²
IBRX Stockholders Have Opportunity to Lead ImmunityBio, Inc. Clas - The National Law Review
IBRX stock enters heavy catalyst phase: Traders brace for key Anktiva decision amid Trump’s FDA turmoil - MSN
ImmunityBio secures exclusive U.S. rights to Tokyo BCG strain By Investing.com - Investing.com Australia
ImmunityBio acquiring U.S. rights to Tokyo strain of BCG (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio secures exclusive U.S. rights to Tokyo BCG strain - Investing.com
ImmunityBio Signs Exclusive U.S. Development And Supply Agreement With Japan BCG Laboratory - marketscreener.com
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States - Business Wire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - Morningstar
IBRX stock jumps after-hours: Bulls cheer 'unstoppable' global expansion amid US regulatory heat for Anktiva - MSN
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class - GlobeNewswire
Vanguard Group Inc. Has $64.90 Million Stake in ImmunityBio, Inc. $IBRX - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - PR Newswire
ImmunityBio stock (US45258J1025): Class action deadline nears amid FDA scrutiny - AD HOC NEWS
IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - PR Newswire
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):